ZYBERNO
Stock Report
Updated Sep 1, 2026

CURIS, INC. (CRIS)

Healthcare • NASDAQ

$1.49

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
17.0/100
POOR BUSINESS
CURIS, INC. (CRIS) scores 17/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-1,975.4%)
Debt-to-Equity (Solvency Risk):GOOD (0.43x)
Operating Margin (Operational Efficiency):CRITICAL (-629.9%)
Return on Capital (Capital Efficiency):CRITICAL (-1,223.2%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

CURIS, INC. (CRIS) stock report — Zyberno Score 17/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:1.49
Market Cap:$3.18M

Valuation Multiples (3)

P/B Ratio:0.68x
P/S Ratio:0.74x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$153.50K

Price Action & Momentum (1)

% of 52-Week High:3.8%
B. Profitability Assessment

Return Metrics (5)

ROA:-167.7%
Reinvestment Rate:13.1%
Fundamental Growth Rate (g):-160.2%

Margin Analysis (3)

Operating Margin Ttm:-629.9%
Net Margin Ttm:-935.6%
Ebitda Margin:-627.1%

TTM Performance (2)

Operating Margin Ttm:-629.9%
Net Margin Ttm:-935.6%

Yield Metrics (2)

Earnings Yield:-$325.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-401.7%
Latest Earnings Filed:2026-08-14

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-6.2%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.49x
Quick Ratio:0.49x
Cash Ratio:0.37x

Leverage Analysis (3)

Debt To Equity Ttm:0.43x
Debt-to-Equity Ratio:0.43x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:-6,951,000.00
Cash And Cash Equivalents:5,073,000.00
Long Term Debt:$1.00M
Net Debt:-$3.03M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $4.31M
Linear Growth: -6.2%
📊 Click to view full CRIS Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$27.17M

Bottom Line Performance (3)

-$40.36M
Income Before Tax:$0.00
Ebitda Ttm:-27,054,000.00

Operating Expenses (5)

Operating Expenses:40,267,000.00
R And D Expense:25,420,000.00
Sga Expense:14,832,000.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:-627.1%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$18.97M
Current Assets:$6.72M
Ppe Net:46,000.00
Goodwill:8,982,000.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:14,275,000.00
Current Liabilities:13,675,000.00
Long Term Debt:$1.00M
Short Term Debt:$1.04M

Equity & Capital (3)

Equity:$4.70M
Retained Earnings:-$1.28B
Common Stock:567,514,300.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:5,388,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:569,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$28.95M$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:$18.94M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:18,941,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:118,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-5.85
-$5.85
Earnings Per Share Ttm:-$18.90

Revenue & Cash Per Share (2)

Sales Per Share Ttm:2.02
Operating Cash Flow Per Share:-$12.74

Book Value & Capital (2)

Book Value Per Share:$2.20
Cash Per Share:2.38

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.18x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:455.87
Cash Conversion Cycle:-2,453.87
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:13.1%
Fundamental Growth Rate (g):-160.2%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-6.2%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-44.4%
C. Company Profile & Context

Corporate Information (6)

Symbol:CRIS
Company Name:CURIS, INC.
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:2.14M
Shares Outstanding Basic:2.14M
Shares Outstanding Diluted:2.14M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 13:18:14 UTC
Data Timestamp:2026-08-21T08:02:24.750241
Scroll to Top